Results 71 to 80 of about 18,591,271 (238)

New psychoactive substances in Vojvodina

, 2023
The term “new psychoactive substances” (NPAS) refers to recently abused psychotropic substances that are not covered by the 1961 Convention on Narcotic Drugs and the 1971 Convention on Psychotropic Substances, but may pose a threat to public health comparable to the threat posed by classic controlled psychoactive substances. The past decade has shown a
Mijatović Jovin, Vesna, Živanović, Dejan, Miljković, Ana, Kelečević, Igor   +3 more
openaire   +1 more source

Antidepressant Prescribing Trends for Adults With and Without Autism in the United Kingdom From 1997 to 2023: A Population‐Based Cohort Study Using Clinical Practice Research Datalink Aurum

Autism Research, EarlyView.
ABSTRACT Antidepressant prescribing and autism diagnoses have increased in recent years. We aimed to describe and compare trends in antidepressant prescribing, indications, doses and durations in autistic and non‐autistic males and females in the United Kingdom (UK) from 1997 to 2023.
Aws Sadik, Golam M. Khandaker, Antonio F. Pardiñas, Michael Lundberg, Brian K. Lee, Cecilia Magnusson, Dheeraj Rai, Paul Madley‐Dowd   +7 more
wiley   +1 more source

Metabolic fate of drugs of abuse and new psychoactive substances: A pilot study on a novel workflow using a zebrafish embryo model combined with human microdosing

British Journal of Clinical Pharmacology, EarlyView.
Aim The aim of this study was to develop a novel workflow to identify human urine biomarkers for drugs of abuse and new psychoactive substances. Metabolites of amphetamine, cocaine, LSD, MDMA, methamphetamine, THC, MDMB‐CHMICA, and MDPPP were first identified in a zebrafish embryo (ZE) metabolism study followed by comparison to most abundant human ...
Simon K. Wellenberg, Tanja M. Gampfer, Lea Wagmann, Philip Schippers, Jennifer Herrmann, Rolf Müller, Folker Westphal, Markus R. Meyer   +7 more
wiley   +1 more source

Taking the cat-and-mouse game to the next level: different perspectives on the introduction of the German New Psychoactive Substances Act

Harm Reduction Journal, 2022
Background To counteract the spread of new psychoactive substances (NPS) and to prevent the emergence of novel substances, specifically designed as a response to the legal control of individual substances, a new law was introduced in Germany in 2016: the 
Regina Kühnl, Darya Aydin, Sabine Horn, Sally Olderbak, Uwe Verthein, Ludwig Kraus   +5 more
doaj   +1 more source

Safety concerns reported by coroners following fentanyl patch fatalities in England, Wales and Northern Ireland between 1997 and 2024

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim To identify safety concerns reported by coroners following fentanyl patch‐related deaths in England, Wales and Northern Ireland, and determine differences in coronial reporting. Methods A systematic case series linking the National Programme on Substance Use Mortality (NPSUM) and the Preventable Deaths Tracker (PDT) (https ...
Eman Mshari, Caroline S. Copeland, Georgia C. Richards   +2 more
wiley   +1 more source

Availability and prevalence of new psychoactive substances [PDF]

, 2016
Cilj istraživanja: Istražiti stavove o poznavanju, dostupnosti i načinu pribavljanja novih psihoaktivnih tvari, te prevalenciju korištenja najčešćih predstavnika s usporedbom prema korištenju klasičnih droga.
Križanac, Zvonimir
core   +3 more sources

Acute toxicity of ADB‐CHMINACA ‐ a case series of patients with pronounced central nervous symptoms including the posterior reversible encephalopathic syndrome

British Journal of Clinical Pharmacology, EarlyView.
Aim This report presents a series of 16 patients who were admitted to the emergency department following confirmed intake of the potent synthetic cannabinoid ADB‐CHMINACA. Methods The cases are drawn from a prospective observational study following the recreational use of synthetic cannabinoids.
Maren Hermanns‐Clausen, Michaela Sommer, Annette Zschiesche, Verena Angerer, Martin Scheu, Florian Eyer, Johannes Nadler, Volker Auwärter   +7 more
wiley   +1 more source

Exploring new avenues: Psychedelic‐assisted therapy for young people

British Journal of Clinical Pharmacology, EarlyView.
Rates of mental illness in young people are increasing, whereas the development of novel mental health treatments has not significantly progressed. Psychedelic‐assisted therapy, using substances such as psilocybin and 3,4‐methylenedioxymethamphetamine (MDMA), has shown potential in the treatment of mental illnesses in the adult population, including ...
Ioanna Artemis Vamvakopoulou, Dasha Nicholls, David J. Nutt, Martina Di Simplicio   +3 more
wiley   +1 more source

Analyzing the Open/Deep Web to Better Understand the New/Novel Psychoactive Substances (NPS) Scenarios: Suggestions from CASSANDRA and NPS.Finder Research Projects

Brain Sciences, 2020
New/novel psychoactive substances (NPS) are defined as new narcotic/psychotropic drugs which are not controlled by the United Nations’ 1961 Narcotic Drugs/1971 Psychotropic Substances conventions, but which may pose a public health threat [...]
Fabrizio Schifano
doaj   +1 more source

An ETH‐LAD trip with unfavourable consequences: A case report

British Journal of Clinical Pharmacology, EarlyView.
Numerous analogues of the psychedelic and internationally controlled hallucinogen LSD have been described; however, only a limited number have been systematically investigated. This report presents the first case with an analytically confirmed ingestion of ETH‐LAD (6‐ethyl‐6‐nor‐lysergic acid diethylamide), the N‐ethyl derivative of LSD.
Johannes Nadler, Michaela Sommer, Annette Zschiesche, Anne Stürzebecher, Christina Grumann, Volker Auwärter, Maren Hermanns‐Clausen   +6 more
wiley   +1 more source